NCT00297921 2013-11-06
A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy
Millennium Pharmaceuticals, Inc.
Phase 1/2 Withdrawn